Phase 2 study for people with Vitiligo

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Novartis Pharmaceuticals
Registry number NCT07431177
Started 9 March 2026 Today 16 October 2026 Estimated completion 6 June 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Novartis Investigative Site Sydney NSW Recruiting
Novartis Investigative Site Waitara NSW Recruiting
Novartis Investigative Site Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years to 99 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 210

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Signed informed consent must be obtained prior to participation in the study

* Male or female as assigned at birth ≥ 18 years of age at the time of screening

* Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosis through physical examination by the investigator

* Non-segmental vitiligo, as assessed at screening, as

* ≥ 0.5% Body Surface Area (BSA) on the face and F-VASI score ≥ 0.5

* ≥ 3% BSA on non-facial areas (minimum of 3% should be calculated in addition to hands and feet) and T-VASI score = 3 to 60

Exclusion Criteria:

* Individuals unable or unwilling to follow the study procedures and/or to complete the study-related questionnaires

* Presence of segmental or mixed vitiligo, or other skin comorbidities that may interfere with study assessments (e.g., hypopigmented mycosis fungoides, genetic diseases with pigmentary aberrations \[such as piebaldism, Waardenburg, etc.\], chemical- or druginduced leukoderma, etc.)

* Previous exposure to biologic drugs directly targeting IL-15 or IL-15 receptors

* Individual who previously attempted or completed depigmentation therapy for NSV

* Use of prohibited medication \& treatments. Other protocol-defined inclusion/exclusion criteria may apply

Dates on the record

Started 9 March 2026
Estimated completion 6 June 2028
Registry last updated 13 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 13 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.